Panfilo vaccine protects NHP against multistrain EBOV and MARV challengesa

GroupInitial challengeBack-challengeClinical findingsDay of death
VirusS/T (%)VirusS/T (%)
1Musoke5/5 (100)SEBOV5/5 (100)All NHP had no symptoms
2ZEBOV5/5 (100)Ci675/5 (100)Small transient ALT increase; small increase in AST in one NHP; all others had no symptoms
Control 1AMusoke0/1 (0)Fever; ALP ↑↑↑; AST ↑↑↑; ALT ↑; GGT ↑8
Control 2AZEBOV0/1 (0)Fever; ALP ↑↑; AST ↑↑6
Control 1BSEBOV0/2 (0)Fever; ALP ↑↑↑; AST ↑↑↑; ALT ↑; GGT ↑6, 8
Control 2BCi670/1 (0)Fever; ALP ↑↑↑; AST ↑↑↑; ALT ↑↑; GGT ↑↑7
  • a Group 1 and 2 NHP were immunized on days 0 and 63 with 4 × 1010 PFU of vaccine(1 × 1010 PFU each of EBO7, EBO2, M8, and M11). EBO7 expresses GPs of SEBOV and ZEBOV, EBO2 expresses two copies of ZEBOV NP, M8 expresses GPs of Ci67 and Ravn, and M11 expresses Musoke GP and NP. Fifteen weeks after immunization, vaccinated animals were divided into two groups, which were challenged with MARV (group 1; Musoke) or EBOV (group 2; ZEBOV). Ten weeks after the primary challenge, group 1 animals were back-challenged with a different EBOV species(SEBOV) and group 2 animals were back-challenged with a different MARV strain (Ci67). Individual control groups were also included for each of the four filovirus challenges. NHP were administered 1,000 PFU of filovirus at each challenge. Rectal temperature and liver enzyme levels were measured pre- and postchallenge, and any changes from baseline were noted as clinical findings. S/T, number of survivors/total challenged; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyltransferase; ↑, 50 to 150 enzyme U/liter of blood; ↑↑, 151 to 400 enzyme U/liter of blood; ↑↑↑, >400 enzyme U/liter of blood.